Discover Enhanced Combinations

Discover preclinical differences in bispecific impact on T cell & tumor cell interactions1

Detect potent functional immune cell subsets to accelerate preclinical decision making.

Download application highlight

Research Area

Development Stage

Discovery

Goal

Identify subtle differences and mechanism in therapies that engage T cells and the tumor microenvironment

How our Award-Winning IsoLight
Single-Cell System is Making a Difference

polyfunctional cell

Solution

PSI revealed differences to enhance decision making

polyfunctional cell

Finding

Enhanced bispecifics elicit more polyfunctional subsets than control when interacting with tumor target

follow our data

Follow Our Data

See the latest published data in Checkpoint & Combination Immunotherapies

PSI identified T cell potency upregulation triggered by novel bispecifics and revealed unique T cell cytokine mechanisms in response to tumor target. PSI was computed for CD4+ and CD8+ T cells; the profiles of both B2-OKT3 and hNKG2D-OKT3 showed significant polyfunctional upregulation relative to the Tz47-2C11 control sample, indicating their effectiveness in triggering a potent T cell response.

Both bispecific profiles are dominated by effector cytokines. hNKG2G-OKT3 stimulation is more potent in terms of polyfunctional strength index (PSI) than B2-OKT3, and sources of upregulation are revealed through the differential cytokine profile (i.e. chemoattractive and effector cytokines). CD4+ and CD8+ cells show the same trend and almost identical cytokine secretion with the exception of IL-5.1

Download application highlight
CD4 PSI and CD8 PSI

Solution

Detect Critical Differences

PAT PCA visualization illustrates the differential T cell upregulation triggered by novel hNKG2D-OKT3 and B2-OKT3 bispecifics, by identifying highly functional cell subsets. CD4+ T cells from the hNKG2D-OKT3 group (orange) secreted polyfunctional effector proteins more frequently than those cultured in the presence of tumor cells and the B2-OKT3 bispecific (blue).

This hNKG2D-OKT3 polyfunctionality includes diverse combinations of secretions, whereas B2-OKT3 overall elicited fewer polyfunctional and more monofunctional secretions. The increased polyfunctional response and T cell potency driven by hNKG2D-OKT3 indicates its potential superiority over B2-OKT3.1

PAT PCA

Request a Seminar

Request a Seminar
Discover IsoLight